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Abstract 
 
 
Objective: The aim of this study was to evaluate the feasibility of a clinical trial investigating 
the effects of acupuncture (AP) and Chinese herbal medicine (CHM) on hot flushes and 
quality of life in postmenopausal women. 
Methods: 40 postmenopausal women reporting at least 20 hot flushes per week were enrolled 
in a randomized controlled trial. They were randomly allocated to receive traditional Chinese 
medicine (TCM) AP, sham AP, verum CHM, or placebo CHM for 12 weeks. Follow-up 
assessment was conducted 12 weeks after intervention. Primary outcome measures included 
hot flush frequency and severity. As a secondary outcome measure the severity of menopausal 
symptoms was assessed using the menopause rating scale (MRS II). 
Results: TCM AP induced a significant decline in all outcome measures from pre- to post-
treatment compared to sham AP (hot flush frequency: P = 0.016; hot flush severity: P = 
0.013; MRS: P < 0.001). In the TCM AP group a larger decrease in MRS-scores persisted 
from pre-treatment to follow-up (P = 0.048). No significant differences were noted between 
the verum and the placebo CHM group. Compared to the verum CHM group there was a 
significant decrease in MRS-scores (P = 0.002) and a trend towards a stronger decrease in hot 
flush severity (P = 0.06) in the TCM AP group from pre- to post-treatment. 
Conclusions: TCM AP was found to be superior to sham AP and to verum CHM in reducing 
menopausal symptoms, while verum CHM showed no significant improvements when 
compared to placebo CHM. 
 
Key Words: Menopause – Acupuncture – Chinese herbal medicine – Hot flushes – 
Vasomotor symptoms – Menopausal symptoms 
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INTRODUCTION 
 
Menopausal women in western countries including Switzerland frequently report menopausal 
symptoms such as hot flushes, insomnia, mood swings, and irritability.1,2 Menopausal 
symptoms in general and hot flushes in particular are known to affect quality of life.3,4 To 
date, hormone therapy (HT) i.e. estrogen therapy (ET) and combined estrogen-progestogen 
therapy (EPT) is regarded as the most effective treatment for hot flushes. 5-7 Moreover, ET 
and EPT have been shown to lower the risk for vertebral and non-vertebral fractures, 
including hip fractures.8,9 The preliminary report of the Woman’s Health Initiative (WHI) that 
EPT increases the risk for breast cancer, stroke and coronary heart disease10 has not been 
confirmed for younger women. In fact, the start of hormone treatment within the so-called 
“window of opportunity” (i.e. < 10 years after menopause, below the age of 60) results in a 
decreased risk of cardiovascular diseases11,12 up to a treatment duration of 10.7 years13 and a 
decrease of total mortality.11,12 In the WHI, ET administered up to 10.7 years was found to 
decrease the risk for breast cancer,13 while EPT did not change significantly breast cancer risk 
up to 7 years in women without prior hormone use.14,15 With peroral ET and EPT, an increase 
of venous thromboembolic events has been reported, but not with transdermal ET.16,17 Stroke 
and dementia are slightly increased when ET or EPT are administered after the age of 60 
years.8,10,18,19 Nevertheless, concerns about HT safety are an important reason for many 
women to refuse or discontinue HT.20,21 In women after breast cancer, HT is 
contraindicated.22 Not surprisingly, many symptomatic women are seeking alternative 
treatment approaches to alleviate their climacteric complaints.23-25 The use of complementary 
and alternative medicine (CAM) in Switzerland is widely spread in the general population, 
with traditional Chinese medicine (TCM) being among the top treatments of the list.26-29 
According to TCM-theory menopausal symptoms are predominantly related to a decline in 
ac
ce
pte
d
kidney Yin, kidney Yang, or a combination of both, often diagnosed with concomitant 
syndromes associated with deficiencies in other organs e.g. spleen and liver.30,31 Hence, when 
applying TCM-treatment modalities such as acupuncture and Chinese herbal medicine (CHM) 
for menopausal symptoms the main focus of the treatment lies on reinforcing the kidneys. 
From a western medical point of view preliminary data are supporting the hypotheses that 
acupuncture may reduce vasomotor symptoms by inhibiting the impact of the hypothalamic-
pituitary-adrenal axis on the hypothalamic-pituitary-ovarian axis32 and by increasing the 
release of endogenous opioids33 potentially influencing the functioning of the hypothalamic 
thermoregulatory center.34 Also, for some CHM preparations treating menopausal symptoms, 
selective activating effects on estrogen receptor-β have been reported with potential 
synergistic effects of the herbal components.35,36 
However, clinical trials investigating effectiveness of acupuncture37-40 and CHM41-45 on 
menopause related symptoms revealed mixed results, probably due to the large variability in 
applied trial methodology, as well as in potential treatment modalities e.g. various 
acupuncture point selections and CHM formulae. 
The main objective of our pilot study was to collect preliminary data in order to assess and 
compare the effects of two TCM treatment modalities for menopausal symptoms, i.e. a semi-
standardized TCM acupuncture treatment, and a standardized 14-herb CHM formula named 
Zhi Mu 14. This pilot study was also performed to evaluate the feasibility of conducting a 
larger clinical trial.  
 
METHODS 
 
Study design 
We conducted a clinical trial at the Women's Hospital of the University of Bern, using a four-
arm prospective, randomized study design investigating the effects of acupuncture (AP) and 
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Zhi Mu 14, a standardized Chinese herbal medicine (CHM) preparation, in postmenopausal 
women experiencing twenty or more hot flushes per week (see Figure 1). AP treatment was 
sham-controlled and single-blinded, while treatment with CHM was placebo-controlled and 
double-blinded. Participants were in the study for a total of 26 weeks, including a run-in 
period with diary collection (2 weeks), a treatment period (12 weeks), and a follow-up period 
after completion of treatment (12 weeks).  Recruitment was carried out from December 2009 
to March 2011 through advertisement of the study on pin boards and on the websites of the 
University of Bern and the University Hospital in Bern. The ethics committee of the Canton 
of Bern, Switzerland has formally approved the research protocol.  
 
Study participants 
Eligible study participants were postmenopausal women who met the following inclusion 
criteria: hot flushes for at least one year, at least twenty hot flushes per week during the run-in 
period, normal gynecological status, at least 12 months of self-defined amenorrhea or after 
hysterectomy, body mass index (BMI = kg/m2) lower than 30, initial score on the Menopause 
Rating Scale (MRS II) of at least 20 points, serum concentration of follicle stimulating 
hormone (FSH) higher than 30 IU/L, and a signed informed consent. The following exclusion 
criteria were applied: hormone therapy (HT) and/or treatment with traditional Chinese 
medicine (TCM) and/or any kind of surgical intervention within 12 weeks of recruitment; 
abnormal genital bleeding; abnormal liver function, bilateral ovariectomy; ongoing 
pregnancy; chronic and/or acute physical diseases and/or mental disorders; abuse of alcohol 
and/or any other addictive substances; recent or planned phytoestrogen enriched diet, intake 
of herbal remedies for treating menopausal symptoms, more than two weeks of planned 
absence during treatment period, simultaneous participation in any other clinical trial. 
 
Procedure 
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Women interested in study participation underwent a telephone screening to determine initial 
eligibility. Informed consent was signed prior to trial start. Initially eligible women received a 
complete written and oral description of the study and were invited to a clinic visit for 
medical examination including heart rate, blood pressure, gynecological examination, and 
laboratory blood tests. Participants received instructions on keeping a 2-week hot flush diary 
to document the frequency and severity of hot flushes. Diary data, gynecological and 
laboratory test results were used to verify eligibility. Eligible women were randomized to one 
of the four study groups. All study participants completed questionnaires at the end of the run-
in period (= baseline), 4 weeks after start of treatment, at the end of treatment, as well as 12 
weeks after treatment completion (= follow-up). At the end of the follow-up period 
participants underwent final medical examination. All participants were instructed not to take 
hormonal medication or to initiate other treatments for their hot flushes during their study 
participation. 
 
Randomization and blinding 
An independent data manager carried out randomization by using a computer generated 
random allocation sequence. Allocation concealment was achieved through sequentially 
numbered, opaque and sealed envelopes. After baseline examination was completed, eligible 
participants were assigned to one of the four study groups by consecutively opening the 
envelopes as they entered the study. The probability to be allocated to the TCM AP, the sham 
AP, the verum CHM or to the placebo CHM group was equal (1:1:1:1). Participants were 
unaware whether they were assigned to a treatment or to a control condition. The study staff 
in charge of data collection, outcome assessment, and preliminary data analysis was also 
blinded. Only the acupuncturist was informed regarding the allocation of patients to TCM and 
sham AP groups. The complete randomization list was placed in a sealed envelope and kept 
there until the study was completed. 
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Interventions 
AP groups 
A licensed acupuncturist (PJ) with 30 years of clinical experience has performed all AP 
treatments in both AP study groups. Participants in the TCM and sham AP group were 
scheduled for 12 weekly treatments. On the first treatment session, women received a TCM 
diagnosis. The standard treatment for women in the TCM AP group comprised the following 
acupuncture points: CV-4, GV-20, GB-20, PC-6, ST-36, SP-6, LI-4, and KI-3. Except for 
CV-4 and GV-20, which are located on the median of the body, all standard treatment points 
were needled bilaterally. In addition to this standardized treatment 7 to 10 supplementary 
acupuncture points were needled based on a persons’ TCM diagnostic category (i.e. “kidney 
Yang with spleen Yang deficiency”: BL-20, BL-23, SP-9, and CV-6 or “kidney Yin with liver 
Yin deficiency”: BL-18, BL-23, HT-6, KI-6, and LR-3) or in accordance to the physicians 
clinical judgment. No more than 24 points were needled during any treatment. Needles were 
inserted through the skin to a depth of 0.2 cm to 1.5 cm depending on target site. With each 
needle insertion the acupuncturist attempted to elicit a de Qi sensation, which is characterized 
as a feeling of soreness, numbness, heaviness, or distention around the stimulated acupuncture 
point. Retention time of the sterile, single-use stainless-steel acupuncture needles (needle 
type: SEIRIN; 0.25 x 30 mm and 0.25 x 40 mm) was 30 min without any additional 
stimulation.  
In the sham AP group acupuncture needles were inserted superficially without attempting to 
elicit a de Qi sensation on seven bilateral target sites that do not correspond to established 
TCM-acupuncture points (see Table, Supplemental Digital Content 1, which describes sham 
acupuncture points in detail). These sham acupuncture points have been previously defined 46 
and used in large clinical trials.47,48 
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CHM groups 
Participants in the verum and placebo CHM group were scheduled for clinic visits at week 1, 
4, 8, and 12 of the treatment period. During these visits a licensed TCM-therapist (LT) with 
20 years of clinical experience set a TCM diagnosis, observed the course of menopausal 
symptoms, inquired whether treatment related side effects occurred, and assessed treatment 
compliance by controlling participants’ daily diary entries and weighting the remaining 
capsules. Women in both CHM groups were instructed to take 3 capsules orally with water 
twice per day i.e. postprandial in the morning and in the evening, and to report daily 
medication intake in their hot flush diary. Women in the CHM group received Zhi Mu 14, a 
standardized CHM preparation comprising 14 plant materials (see Table, Supplemental 
Digital Content 2, which describes the composition of the CHM formula Zhi Mu 14 in detail) 
that has been approved by the Swiss Agency for Therapeutic Products (Swissmedic) for 
therapeutic use. The formulation of Zh Mu 14 is based on two modified classic formulas i.e. 
“Gan Mai Da Zao Tang” and “Qing Hao Bie Jia Tang” designed to treat hot flushes, night 
sweats, insomnia, mood swings, irritability, and emotional instability resulting from kidney 
yin deficiency.49 The administered dosage of 3 g of herbal extract granules per day is 
equivalent to 15g of dry herb. Participants in the placebo CHM group received placebo 
capsules containing starch (Amylum Maydis) and caramel as a color tracer. This placebo 
mixture has no known effects on menopausal symptoms. Both placebo and CHM capsules 
were identical in their appearance and were prepared by Sheng Foong Pharmaceutical Ltd., 
Taiwan on behalf of China Medical Ltd., Switzerland. In accordance with herbal Good 
Manufacturing Practice (GMP) genuineness and quality of each herbal component was 
controlled by conducting thin-layer chromatographic analysis and tests for heavy metal 
contamination, microbial traces, and pesticide residues. 
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Outcome measures 
Primary outcome measures were severity and frequency of hot flushes per week. An adapted 
form of a daily hot flush diary frequently used in prior studies was used for data collection.50 
A hot flush severity score has been calculated as the sum of the number of self-reported hot 
flushes multiplied by severity. The applied hot flush severity rating scale ranged from 1 to 3 
to distinguish between mild (= 1; heat sensation without sweating and disruption of activity), 
moderate (= 2; heat sensation accompanied by sweating but no disruption of activity), and 
severe (= 3; heat sensation accompanied by sweating and disruption of activity) hot flushes. 
Participants were asked to record the occurrence and severity of each hot flush during the run-
in, the treatment, as well as during the 4th, 8th and 12th week of the follow-up period of the 
trial. During the follow-up period participants were reminded by phone call to re-uptake their 
diary entries. 
As a secondary outcome measure menopause related quality of life was assessed using the 
validated Menopause Rating Scale (MRS II).51-54 This self-report instrument comprises 11 
items and assesses the presence and intensity of menopausal symptoms on a 5-point rating 
scale ranging from 0 (= no symptom) to 4 (= very severe symptom). The MRS II sum score 
represents an overall index of severity of climacteric related complaints, i.e. MRS II sum 
score of 0 to 4 (= no, little), of 5 to 8 (= mild), of 9 to 16 (= moderate), of ≥ 17 (= severe). 
Additionally to the MRS II sum score, three independent subscales i.e. psychological, somato-
vegetative, and urogenital subscale indicate domain specific symptom severity.  
Mean reference values for the MRS II scores in European populations are 7.2 for MRS II sum 
score, 2.9 for the psychological, 3.3 for the somato-vegetative, and 1.0 for the urogenital 
subscale. These values are comparable to the mean MRS II reference values for North 
America.54 
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Statistical analyses 
Data analysis was conducted using SPSS (version 20) statistical software package for 
Macintosh (IBM SPSS Statistics, Somers, NY, USA). The level of significance was set at P < 
0.05. Differences in group characteristics and baseline values were analyzed using χ2 Tests 
for dichotomous variables, Kurskal-Wallis Tests for continuous variables with skewed 
distributions, and ANOVAs for normally distributed continuous variables. To compare 
treatment effects on primary and secondary outcome measures between the TCM and sham 
AP group, between the verum and placebo CHM group, as well as between the TCM AP and 
the verum CHM group mean change values have been calculated for each study group by 
subtracting pre-treatment baseline values from post-treatment values, and from follow-up 
values. Between group differences in mean change values have been analyzed using Mann–
Whitney U Tests. Within group changes in outcome measures have been analyzed using 
Wilcoxon Tests.  
 
 
RESULTS 
 
Participants 
Of the 63 applicants who underwent a telephone screening, 40 participants fulfilled eligibility 
criteria and successfully completed baseline assessment. They were randomly assigned to one 
of the four study groups. Study retention was excellent with 39 out of 40 women (97.5%) 
remaining in the study. Only one participant of the placebo CHM group discontinued prior to 
treatment start due to lack of motivation. Complete data sets of 39 participants have been 
considered in statistical analysis (Figure 1). Except for the frequency of TCM diagnoses, the 
four study groups did not significantly differ in group and baseline characteristics (Table 2). 
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14 women had other TCM diagnoses with 12 of them being diagnosed of kidney yin and 
spleen qi deficiency. On average participants in the verum CHM group took 92.3% (SD ± 
10.0) and those in the placebo CHM group 89.5% (SD ± 14.2) of the prescribed capsules. The 
compliance rate for the weekly regimen in the TCM AP group was 94.2% (SD ± 6.9) and 
92.6% (SD ± 6.2) in the sham AP group. 
 
Changes in hot flushes 
Figures 2a and b show the course of weekly hot flush severity scores and weekly hot flush 
frequencies in all four study groups. As within group analyses revealed participants in the 
TCM AP group reported a significant decrease of hot flush severity and frequency from pre- 
to post-treatment (Z = -2.803, P = 0.005; Z = -2.701, P = 0.007, respectively) as well as from 
pre-treatment to follow-up assessment (Z = -2.497, P = 0.013; Z = -2.191, P = 0.028, 
respectively). In the sham AP group a trend towards a decrease of hot flush severity and 
frequency was observed from pre- to post-treatment (P’s = 0.09). In this group decrease in hot 
flush severity from pre-treatment to follow-up assessment was significant (Z = -2.497, P = 
0.013), while decrease in hot flush frequency from pre-treatment to follow-up assessment 
remained on a trend level (P = 0.06). In the verum CHM group participants reported a 
significant decrease of hot flush severity from pre- to post-treatment (Z = -1.988, P = 0.047) 
as well as from pre-treatment to follow-up assessment (Z = 2.040, P = 0.041), while this was 
not the case for hot flush frequency (P’s > 0.08). No significant changes in hot flush measures 
have been found in the placebo CHM group (P’s > 0.40). 
Between group analyses showed, that in comparison to the sham AP group participants in the 
TCM AP group reported a significantly greater decline in hot flush severity (P = 0.013) and 
frequency (P = 0.016) from pre- to post-treatment but not from pre-treatment to follow-up 
assessment (P’s > 0.24; see Table 2a). No significant differences have been found between the 
verum and the placebo CHM group in any hot flush mean change value (P’s > 0.42; see Table 
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2b). When compared to the verum CHM group a trend towards a greater decline of hot flush 
severity from pre- to post-treatment has been observed in the TCM AP group (P = 0.06), 
while no significant group differences have been found for the remaining hot flush mean 
change values (P’s > 0.13).  
 
 
Changes in menopause related quality of life (MRS II scores) 
Within group analyses revealed the strongest decrease in MRS II sum score in the TCM AP 
group from pre- to post-treatment, and from pre-treatment to follow-up (P’s = 0.005). 
Significant decreases in MRS II sum score from pre- to post-treatment (P’s ≤ 0.025) and from 
pre treatment to follow-up assessment (P’s ≤ 0.019) have also been found in the verum CHM 
and the sham AP group, while in the placebo CHM group a significant reduction of the MRS 
II sum score was observed for the period from pre-treatment to follow-up assessment (P = 
0.036) but without significant changes in any MRS II subscale scores. In the TCM AP group 
all MRS II subscale scores decreased significantly from pre- to post-treatment (P’s ≤ 0.007) 
and to follow-up assessment respectively (P’s ≤ 0.013). In the sham AP group the 
psychological and somato-vegetative MRS II subscale scores decreased significantly from 
pre- to post-treatment (P’s ≤ 0.017) and to follow-up assessment respectively (P’s ≤ 0.005), 
while the MRS II urogenital subscale score decreased significantly from pre-treatment to 
follow-up assessment only (P = 0.012). In the verum CHM group a significant decrease from 
pre- to post-treatment and to follow-up assessment respectively was found in MRS II somato-
vegetative subscale scores (P’s ≤ 0.021), while the scores of the MRS II psychological and 
urogenital subscales decreased significantly from pre-treatment to follow-up assessment only 
(P’s ≤ 0.020). In the placebo CHM group a significant decrease in the MRS II sum score (P = 
0.036) but not in the subscale scores (P’s ≥ 0.08). 
Participants in the TCM AP group reported a significantly higher decrease in the MRS II sum 
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score from pre- to post-treatment (P < 0.001), as well as from pre-treatment to follow-up 
assessment (P = 0.048) when compared to the sham AP group.  In the TCM AP group a 
significantly greater decline in all MRS II subscale scores was measured from pre- to post-
treatment (P’s < 0.004). At follow-up assessment significant group differences in mean 
change values of the MRS II somato-vegetative and the urogenital subscales persisted (P = 
0.014, P = 0.035 respectively; see Table 2a). Between the verum and the placebo CHM group 
no significant group differences in MRS II related mean change values have been found (P’s 
≥ 0.10; see Table 2b). In comparison to the verum CHM group participants in the TCM AP 
group indicated a significantly higher decrease in the MRS II sum score (U = 9.5, Z = -3.072, 
P = 0.002), as well as in all three MRS II subscale scores from pre- to post-treatment 
(psychological subscale: U = 12.5, Z = -2.866, P = 0.004; somato-vegetative subscale: U = 
16.0, Z = -2.591, P = 0.010; urogenital subscale: U = 15.0, Z = -2.675, P = 0.007). No 
significant differences in MRS II mean change values between the verum CHM and the TCM 
AP group have been found from pre-treatment to follow-up assessment (P’s ≥ 0.10). 
 
Adverse events 
In one participant in the verum CHM group a dysplasia of the squamous epithelium was 
diagnosed at the final gynecological examination at follow-up assessment. This serious 
adverse event, however, is not thought to be related to the trial medication. Only one 
participant in the sham AP group reported a mild adverse event by stating pain sensation at 
needle insertion. 
 
Blinding 
At follow-up assessment all participants were asked to indicate to which study group they 
believe they were assigned to. In the TCM AP group 50% of the participants guessed 
correctly, 40% could not tell, and 10% guessed incorrectly. In the sham AP group 10% of the 
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participants guessed their group allocation correctly, 40% could not tell, and 50% guessed 
incorrectly. In the verum CHM group 40% of the participants guessed their group assignment 
correctly and 60% guessed incorrectly. In the placebo CHM group 89% of the participants 
guessed their group allocation correctly, only 11% made a wrong guess. 
 
 
DISCUSSION 
 
Our findings demonstrate a significant improvement of hot flush severity and frequency, as 
well as other menopausal symptoms in postmenopausal women after 12 weeks of TCM AP 
treatment in comparison to sham AP. Moreover we measured persisting long-term effects of 
TCM AP on attenuation of overall, somato-vegetative and urogenital menopausal symptom 
severity at 12 weeks follow-up assessment. When comparing the effects of TCM AP with 
verum CHM, TCM AP was found to be superior to CHM in terms of significantly stronger 
decreases in all MRS II subscale scores, and a trend towards a stronger reduction in hot flush 
severity from pre- to post-treatment. No significant effects were found for verum CHM 
compared to placebo CHM. Interventions in all study arms were well tolerated. 
Unlike several sham-controlled AP studies32, 34, 37,55-58 our data suggest that TCM AP is 
superior to sham AP in reducing severity and frequency of menopause related symptoms. This 
preliminary finding is in line with results from two recently published randomized sham-
controlled AP trials emphasizing not only clinical effectiveness of TCM AP by reducing hot 
flush frequency and overall menopausal symptom severity by 60 to 95% but also underlining 
its treatment specific efficacy.38,39 Taken into account that sham AP interventions are not 
considered to be physiologically inert control interventions59 physiologic treatment effects of 
AP are likely to be underestimated. In our trial a semi-standardized treatment protocol was 
applied by a highly experienced acupuncturist, which might have contributed to the 
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pronounced treatment effects of TCM AP.60 With respect to the reported postmenopausal HT 
induced reduction of hot flush severity and frequency by approximately 87% and 75% 
respectively,61 and of MRS II sum score by 30% to 36% from baseline,53,62 the observed 
attenuation in menopausal symptoms in the TCM AP treatment group (i.e. reduction of hot 
flush severity and frequency by 64.3% and 55.9% respectively, and of MRS II sum score by 
66.3% from baseline) plead for acupuncture as a clinically meaningful intervention for 
alleviating menopausal symptoms. However, further comparative effectiveness research is 
needed to prove its clinical significance. 
Even though within group analyses revealed a significant decrease of hot flush severity and 
frequency as well as of MRS II scores in the verum but not in the placebo CHM group, both 
study groups did not differ significantly in outcome measures when compared with each 
other. A possible explanation for this finding could be the limits of our clinical trial setup. 
Since we used a predefined CHM prescription (Zhi Mu 14 capsules) we did not have the 
possibility to individually adapt the treatment provision, i.e. formula and dosage of the 
formula depending on the patients’ diagnoses, like we did in the TCM AP group. In fact, only 
three out of ten women in the verum CHM group were diagnosed of kidney yin and liver yin 
deficiency, while five women were diagnosed of kidney yin and spleen qi deficiency. 
Therefore a more individually tailored approach with adaptable herbal formula or inclusion 
criteria determined according to a specific TCM diagnosis (hot flushes can be based on 
different TCM diagnoses) would be more accurate for further studies. Despite the good 
treatment compliance in the verum CHM group it might be that the standard dosage of the 
trial medication was inadequate. Also, taken into account the small sample size of our pilot 
study, this non-significant finding should be treated with care, as we cannot rule out a type II 
error. Further basic and clinical studies investigating the effects of Zhi Mu 14 are warranted, 
as potential therapeutic effects of some herbal components of the trial medication have 
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already been documented, e.g. estrogenic activity of Rhizoma Anemarrhenae (Zhi Mu)63 and 
sedative-hypnotic effects of Semen Ziziphy Spinosae (Suan Zao Ren).64 
TCM AP was found to be superior in reducing menopausal symptoms when compared to the 
verum CHM. This result might be due to different mode of actions of the two treatment 
approaches. Hence, future research would strongly benefit from including the assessment of 
biological markers related to the postulated mechanistic pathways.  
A non-specific treatment effect of approximately 30% reduction in hot flush severity from 
pre- to post-treatment was observed in the sham AP group, which is in line with the reported 
effects of sham AP in some previously conducted randomized sham-controlled trials 
(reduction of 20 to 40%).55-57 Interestingly, unlike other randomized placebo-controlled CHM 
trials in postmenopausal women, where placebo effects of approximately 30% reduction of 
hot flush severity were documented42-44 we have found no such effect in our placebo CHM 
group. This might be due to participants’ potentially lower treatment expectations in this 
study group. Furthermore, the fact that eight of nine participants correctly assumed to be 
allocated to the placebo CHM group supports the notion of a reduced treatment expectation in 
this group. Future trials should consider repeated measuring of treatment expectations. 
Moreover, blinding of treatment allocation is likely to be enhanced by ensuring high 
similarity between placebo and verum CHM medication not only in look but also in taste and 
smell.42,65 The significant decrease in the MRS II sum score from pre-treatment to follow-up 
assessment in the CHM placebo group is likely to reflect the natural course of menopause 
related symptom severity. However, to obtain precise data about the natural course a further 
control group receiving usual care should have been included in the study design, which 
would also allow a more accurate estimation of the sum of unspecific treatment effects other 
than time effects.66 
The main strength of our trial is the four-armed placebo- and sham-controlled study design 
with a follow-up period of 12 weeks. Moreover, as study groups did not differ neither in their 
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group characteristics nor in baseline values randomization of participants is considered to be 
successful. Also, participants’ adherence to the study protocol was excellent. 
The following limitations need to be considered when interpreting the findings of this pilot 
study. First, we investigated the effects of a standardized CHM preparation and did not take 
into account TCM-treatment principles where the administered formula would have been 
modified at the beginning, as well as in the course of the treatment according to participants’ 
individual constitution, overall symptoms, and CHM treatment responses. To the best of our 
knowledge, to date only one randomized placebo-controlled CHM trial with an individualized 
TCM based treatment approach has been conducted in postmenopausal women showing 
stronger symptom reducing effects in the verum CHM group.43A comparison of the efficacy 
of both a standardized and an individualized treatment approach would certainly elucidate this 
issue. Second, since hepatotoxic adverse events have been reported in association with the 
intake of CHM67 we conducted laboratory blood analyses prior to treatment onset to rule out 
pre-existing abnormal liver functions. As analyses were not repeated until the end of the 
follow-up period the impact of the Zhi Mu 14 compound on liver functioning during the 
treatment could not have been evaluated. However, regarding CHM treatment safety no 
adverse events were reported in the verum CHM group during and after the treatment and no 
abnormal laboratory results were noted at follow-up assessment 12 weeks after treatment 
completion indicating long-term safety of the investigated CHM formula. Third, for the same 
reason as stated above no treatment effect on hormone levels from pre- to post-intervention 
was evaluated. Finally, the comparison of the two interventions TCM AP and verum CHM is 
suboptimal, since participants in the TCM AP group had significantly more treatment visits 
than those in the verum CHM group. Also the extent to which TCM treatment principles 
could have been considered was larger in the semi-standardized TCM AP treatment compared 
to the prescription of a standardized CHM preparation. Therefore these findings should be 
interpreted with care. 
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CONCLUSIONS 
 
In this pilot study TCM AP treatment of 12 weeks has led to a general attenuation of 
menopausal symptoms including a substantial reduction in hot flush severity of more than 
60% in postmenopausal women. This treatment type was found to be superior to sham AP and 
verum CHM. Former did not differ from placebo CHM. Due to the small sample size the 
generalizability of our results is limited. Our pilot data, however, support the feasibility of 
conducting a large scale multicenter trial to validate the preliminary findings. 
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FIGURE LEGENDS 
 
Legend to Figure 2a and 2b:  
TCM = traditional Chinese medicine; AP = acupuncture; CHM = Chinese herbal medicine; a) 
= within group changes from baseline to post intervention; b) within group changes from 
baseline to follow-up; c) between groups changes within the same intervention method from 
baseline to post intervention; d) between groups changes within the same intervention method 
from baseline to follow-up; ns = not significant; * = P < 0.05; ** = P < 0.01. 
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Figure 1: Flow diagram for the progress through the phases of the randomized trial based on the CONSORT recommendations 
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Figure 2a: Mean weekly hot flush severity scores as percentage of baseline 
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Figure 2b: Mean weekly hot flush frequency scores as percentage of baseline 
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Table 1: Group and baseline characteristics of the four study groups 
Characteristics TCM AP 
(n = 10) 
Sham AP 
(n = 10) 
Verum CHM 
(n = 10) 
Placebo CHM 
(n = 9) 
Complete sample  
(n = 39) 
P 
Current age (years) 54.70 ± 4.11 51.20 ± 2.86 53.10 ± 2.81 53.44 ± 3.39 53.10 ± 3.45 0.15 
BMI (kg/m2) 24.03 ± 2.34 21.58 ± 2.12 21.72 ± 2.03 23.03 ± 2.72 22.58 ± 2.44 0.07 
Smoking (yes / no) 1 / 9 1 / 9 1 / 9 3 / 6 6 / 39 0.41 
Years since last menstruation  4.4 ± 2.7 5.8 ± 6.7 6.4 ± 5.2 7.2 ± 5.8 5.9 ± 5.2 0.69 
Frequency of hot flushes (per week) 63.20 ± 43.77 54.80 ± 31.71 65.50 ± 36.57 54.83 ± 34.43 59.71 ± 35.80 0.88 
Severity of hot flushes (per week) 119.55 ± 79.31 102.75 ± 73.21 121.00 ± 63.65 119.67 ± 107.97 115.64 ± 78.95 0.95 
MRS II sum score 25.20 ± 3.29 24.00 ± 3.86 25.70 ± 6.43 23.11 ± 2.62 24.54 ± 4.29 0.56 
Heart rate (beats per minute) 64.9 ± 8.0 67.2 ± 8.6 63.6 ± 8.9 67.4 ± 8.8 65.7 ± 8.4 0.72 
Systolic blood pressure (mmHg) 106.7 ± 19.1 111.3 ± 17.6 109.5 ± 11.6 112.8 ± 18.9 110.0 ± 16.5 0.88 
Diastolic blood pressure (mmHg) 73.6 ± 13.9 71.5 ± 10.6 71.1 ± 8.2 70.6 ± 12.3 71.7 ± 11.0 0.94 
FSH (IU/L) 85.33 ± 21.84 93.71 ± 31.49 71.61 ± 16.51 89.20 ± 29.16 84.85 ± 25.74 0.26 
LH (IU/L) 39.76 ± 14.35 46.86 ± 15.60 37.30 ± 9.71 41.49 ± 12.32 41.35 ± 13.18 0.43 
Estradiol (pmol/L) 27.70 ± 13.15 58.70 ± 54.40 41.50 ± 23.47 67.56 ± 48.21 48.38 ± 40.02 0.12 
ALP (IU/L) 74.20 ± 25.99 61.00 ± 9.37 69.80 ± 10.12 68.11 ± 11.16 68.28 ± 15.97 0.32 
ASAT (IU/L) 25.00 ± 4.50 25.50 ± 4.17 26.50 ± 5.62 25.78 ± 7.54 25.69 ± 5.36 0.94 
ALAT (IU/L) 23.50 ± 8.46 18.20 ± 5.05 21.70 ± 13.65 24.33 ± 22.78 21.87 ± 13.49 0.77 
Creatinin (µmol/L) 68.70 ± 9.89 62.50 ± 9.72 62.00 ± 8.18 66.56 ± 6.58 64.90 ± 8.87 0.27 
TCM diagnoses (yes / no) 
- kidney yin and liver yin deficiency 
- kidney yang and spleen yang deficiency 
- other TCM diagnoses 
 
4 / 6 
6 / 4 
0 / 10 
 
7 / 3 
3 / 7 
0 / 10 
 
3 / 7 
1 / 9 
6 / 4 
 
1 / 8 
0 / 9 
8 / 1 
 
15 / 24 
10 / 29 
14 / 25 
 
0.06 
0.014 
<0.001 
All continuous data are presented as mean ± SD; P-values for continuous data refer to ANOVA, and for dichotomous data to Χ 2-Test; TCM = traditional Chinese medicine; 
AP = acupuncture; CHM = Chinese herbal medicine; BMI = body mass index; FSH = follicle stimulating hormone; LH = luteinizing hormone; MRS = Menopause Rating 
Scale; ALP = alkaline phosphatase; ASAT = aspartate aminotransferase; ALAT = alanine aminotransferase 
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Table 2a: Changes in hot flushes and MRS II scores in acupuncture (AP) groups 
 
Variable 
Mean change values  ± SD  
U 
 
Z 
 
Pa ∆ TCM AP  
(n = 10) 
∆ Sham AP  
(n = 10) 
Hot flushes severity 
- week 12 (post intervention) - 76.9 ± 49.6 - 31.7 ± 57.6 17.0 - 2.495 0.013 
- week 24 (follow-up) - 70.4 ± 70.5 - 44.3 ± 57.0 34.5 - 1.172 0.24 
Hot flushes frequency 
   - week 12 - 35.3 ± 30.2 - 11.3 ± 21.7 18.0 - 2.420 0.016 
   - week 24 - 31.3 ± 40.0 - 16.8 ± 27.5 35.5 - 1.097 0.27 
MRS II total score 
   - week 12 - 16.7 ± 5.5 - 4.2 ± 4.3 0.0 - 3.788 <0.001 
   - week 24 - 14.2 ± 6.1 - 9.5 ± 3.7 24.0 - 1.975 0.048 
MRS II psychological subscale  
   - week 12 - 5.7 ± 3.2 - 1.3 ± 2.2 12.5 - 2.861 0.004 
   - week 24 - 4.3 ± 4.3 - 3.8 ± 1.9 38.5 - 0.880 0.38 
MRS II somatio-vegetative subscale 
   - week 12 - 7.3 ± 3.0 - 1.9 ± 2.2 5.0 - 3.422 0.001 
   - week 24 - 6.4 ± 2.2 - 3.7 ± 1.6 18.0 - 2.462 0.014 
MRS II urogenital subscale 
   - week 12 - 3.7 ± 1.3 - 1.0 ± 1.8 11.0 - 2.982 0.003 
   - week 24 - 3.5 ± 1.2 - 2.0 ± 1.9 22.5 - 2.111 0.035 
a P-values refer to Mann-Whitney U Test 
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Table 2b: Changes in hot flushes and MRS II scores in Chinese herbal medicine (CHM) 
interventions 
 
Variable 
Mean change values  ± SD  
U 
 
Z 
 
Pa ∆ Verum CHM 
(n = 10) 
∆ Placebo CHM  
(n = 9) 
Hot flushes severity 
- week 12 (post intervention) - 36.8 ± 49.3 - 2.4 ± 82.9 36.5 - 0.695 0.49 
- week 24 (follow-up) - 41.4 ± 69.2 - 24.4 ± 65.2 38.5 - 0.531 0.60 
Hot flushes frequency 
   - week 12 -15.4 ± 21.84 3.2 ± 44.5 39.0 - 0.490 0.62 
   - week 24 - 20.2 ± 41.24 - 4.8 ± 24.8 31.0 - 0.800 0.42 
MRS II total score 
   - week 12 - 5.6 ± 6.70 - 4.1 ± 7.0 41.5 - 0.287 0.78 
   - week 24 - 8.9 ± 9.39 - 4.6 ± 5.3 32.5 - 1.022 0.31 
MRS II psychological subscale  
   - week 12 - 1.5 ± 2.5 - 1.9 ± 4.2 44.5 - 0.041 0.97 
   - week 24 - 2.2 ± 3.2 - 2.7 ± 3.7  41.0 - 0.330 0.74 
MRS II somato-vegetative subscale 
   - week 12 - 3.0 ± 3.3 - 1.11 ± 3.5 30.0 - 1.232 0.22 
   - week 24 - 4.7 ± 4.5 - 0.78 ± 2.0 25.0 - 1.665 0.10 
MRS II urogenital subscale 
   - week 12 - 1.1 ± 2.2 - 1.1 ± 0.9 40.5 - 0.384 0.70 
   - week 24 - 2.0 ± 2.8 - 1.1 ± 1.2 34.0 - 0.914 0.36 
a P-values refer to Mann-Whitney U Test 
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Supplemental Digital Content 1: Table that describes sham acupuncture points 
 
Name of the sham 
acupuncture point 
Location 
Deltoideus In the middle of the insertion line of M. deltoideus (LI-14) and Acromion 
Upper Arm 2 cun laterally (radial) of LU-3 
Forearm 1 cun ulnar of the proximal third of the line between HT-3 and HT-7 
Spina Iliaca 2 cun above the spina iliaca anterior superior in vertical line to the arch of left ribs  
Upper Leg I 6 cun above the upper edge of the patella (between the spleen and stomach meridian) 
Upper Leg II 4 cun above the upper edge of the patella 
Upper Leg III 2 cun dorsally of GB-31 (avoidance of bladder meridian) 
cun =  an acupuncture term for “body inch” corresponding to the width of the inter-phalangeal joint of 
patient’s thumb; LI = large intestine meridian;  LU = lung meridian; HT = heart meridian; GB = gall bladder 
meridian 
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Supplemental Digital Content 2: Table that lists details of the Chinese herbal medicine 
(CHM) formula Zhi Mu 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Herb name  
Latin name Chinese name Amount in % 
Radix Rehmanniae Sheng Di Huang 11% 
Rhizoma Anemarrhenae Zhi Mu 10% 
Semen Ziziphi Spinosae Suan Zao Ren 10% 
Radix et Rhizoma Cynanchi Atrati  Bai Wei 10% 
Radix et Rhizoma Glycyrrhizae Gan Cao 8% 
Caulis Polygoni Multiflori Shou Wu Teng 7% 
Radix Paeoniae Alba  Bai Shao 7% 
Cortex Lycii Di Gu Pi 6% 
Cortex Phellodendri Chinensis Huang Bo 6% 
Fructus Tritici Levis Fu Xiao Mai 5% 
Cortex Moutan Mu Dan Pi 5% 
Herba Artemisiae Annuae Qing Hao 5% 
Radix Bupleuri  Chai Hu 5% 
Fructus Jujubae  Da Zao 5% 
